A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2015
At a glance
- Drugs Vx 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Dec 2015 New trial record